Dicerna Pharmaceuticals Inc
NASDAQ:DRNA 3:59:58 PM EDT
| Market Cap (Intraday) | 1.56B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $20.97 |
| 50-Day MA | $26.81 |
| 200-Day MA | $27.76 |
Dicerna Pharmaceuticals Inc Stock, NASDAQ:DRNA
75 Hayden Avenue, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.621.8097
Number of Employees: 302
Description
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.